Compare RSSS & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RSSS | ONCY |
|---|---|---|
| Founded | 2006 | 1998 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Business Services | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.3M | 94.0M |
| IPO Year | N/A | 1999 |
| Metric | RSSS | ONCY |
|---|---|---|
| Price | $2.90 | $0.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $5.00 | ★ $6.00 |
| AVG Volume (30 Days) | 67.9K | ★ 583.5K |
| Earning Date | 02-12-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $49,325,684.00 | N/A |
| Revenue This Year | $4.92 | N/A |
| Revenue Next Year | $7.09 | N/A |
| P/E Ratio | $73.00 | ★ N/A |
| Revenue Growth | ★ 5.83 | N/A |
| 52 Week Low | $2.32 | $0.33 |
| 52 Week High | $4.24 | $1.51 |
| Indicator | RSSS | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 46.77 | 43.64 |
| Support Level | $2.82 | $0.86 |
| Resistance Level | $3.04 | $1.00 |
| Average True Range (ATR) | 0.12 | 0.05 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 35.45 | 28.41 |
Research Solutions Inc is a holding company. The company provides vertical software-as-a-service ("SaaS") and artificial intelligence ("AI") solutions, providing software and related services to help research-intensive organizations simplify the research process, save time, and money. The company operates in a single segment, which derives its revenue from subscription fees from its cloud-based SaaS Platforms and transactional service fees for the electronic delivery of single articles. The company generates the majority of its revenue from the Transactions. Geographically, the company generates the majority of its revenue from the United States, followed by Europe.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.